RU2005130169A - Тетрациклические производные бензамида и способы их применения - Google Patents
Тетрациклические производные бензамида и способы их применения Download PDFInfo
- Publication number
- RU2005130169A RU2005130169A RU2005130169/04A RU2005130169A RU2005130169A RU 2005130169 A RU2005130169 A RU 2005130169A RU 2005130169/04 A RU2005130169/04 A RU 2005130169/04A RU 2005130169 A RU2005130169 A RU 2005130169A RU 2005130169 A RU2005130169 A RU 2005130169A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- compound
- pharmaceutically acceptable
- substituted
- acceptable salt
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 159
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 93
- 150000003839 salts Chemical class 0.000 claims 86
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 76
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 66
- 125000000217 alkyl group Chemical group 0.000 claims 43
- 208000002249 Diabetes Complications Diseases 0.000 claims 31
- 229910052736 halogen Inorganic materials 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 206010012655 Diabetic complications Diseases 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 208000027866 inflammatory disease Diseases 0.000 claims 16
- 230000000302 ischemic effect Effects 0.000 claims 16
- 230000010410 reperfusion Effects 0.000 claims 16
- 208000019553 vascular disease Diseases 0.000 claims 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 8
- 208000001647 Renal Insufficiency Diseases 0.000 claims 8
- 150000001412 amines Chemical class 0.000 claims 8
- 230000001684 chronic effect Effects 0.000 claims 8
- 208000020832 chronic kidney disease Diseases 0.000 claims 8
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 8
- 201000006370 kidney failure Diseases 0.000 claims 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229930182470 glycoside Natural products 0.000 claims 2
- 150000002338 glycosides Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 0 CC(c1c(*)c(*)c(*)c(*)c11)C(N2)=C1c1c(*)c(*)c(*)c(*)c1C2=* Chemical compound CC(c1c(*)c(*)c(*)c(*)c11)C(N2)=C1c1c(*)c(*)c(*)c(*)c1C2=* 0.000 description 8
- MUXUAGKHVVSZBY-UHFFFAOYSA-N COc(cc1)cc2c1c(nc(c1c3cccc1)OC)c3[o]2 Chemical compound COc(cc1)cc2c1c(nc(c1c3cccc1)OC)c3[o]2 MUXUAGKHVVSZBY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45092503P | 2003-02-28 | 2003-02-28 | |
| US60/450,925 | 2003-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005130169A true RU2005130169A (ru) | 2006-05-10 |
Family
ID=34102592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005130169/04A RU2005130169A (ru) | 2003-02-28 | 2004-02-26 | Тетрациклические производные бензамида и способы их применения |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7217709B2 (https=) |
| EP (1) | EP1603567A4 (https=) |
| JP (1) | JP2007501857A (https=) |
| KR (1) | KR20050118169A (https=) |
| CN (1) | CN100398519C (https=) |
| AU (1) | AU2004258801A1 (https=) |
| BR (1) | BRPI0407757A (https=) |
| CA (1) | CA2517260A1 (https=) |
| PL (1) | PL378331A1 (https=) |
| RU (1) | RU2005130169A (https=) |
| WO (1) | WO2005009398A2 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6956035B2 (en) * | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
| US20030096833A1 (en) * | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
| JP2007501857A (ja) * | 2003-02-28 | 2007-02-01 | イノテック ファーマシューティカルズ コーポレーション | 四環系ベンズアミド誘導体およびその使用方法 |
| EA200601558A1 (ru) * | 2004-02-26 | 2007-08-31 | Инотек Фармасьютикалз Корпорейшн | Производные изохинолинов и способы их использования |
| US20050261288A1 (en) * | 2004-02-26 | 2005-11-24 | Prakash Jagtap | Tetracyclic lactam derivatives and uses thereof |
| CA2571001A1 (en) * | 2004-06-16 | 2006-01-26 | Inotek Pharmaceuticals Corporation | Methods for treating or preventing erectile dysfunction or urinary incontinence |
| WO2006093677A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Tetracyclic sulfonamide compounds and methods of use thereof |
| RU2007135362A (ru) * | 2005-02-25 | 2009-03-27 | Инотек Фармасьютикалз Корпорейшн (Us) | Тетрациклические амино- и карбоксамидосоединения и способ их применения |
| JP2008531561A (ja) * | 2005-02-25 | 2008-08-14 | イノテック ファーマシューティカルズ コーポレイション | イソキノリン化合物およびその使用方法 |
| CA2617101A1 (en) * | 2005-08-08 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Method for the protection against the risk of cardiac disorders comprising administration of tiotropium salts |
| CN101316592A (zh) * | 2005-08-24 | 2008-12-03 | 伊诺泰克制药公司 | 茚并异喹啉酮类似物及其用法 |
| CA2629530C (en) | 2005-11-14 | 2014-07-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | N-substituted indenoisoquinolines and syntheses thereof |
| US9399660B2 (en) | 2005-11-14 | 2016-07-26 | Purdue Research Foundation | N-substituted indenoisoquinolines and syntheses thereof |
| WO2007117289A2 (en) * | 2005-12-14 | 2007-10-18 | Inotek Pharmaceuticals Corporation | Methods for treating or preventing erectile dysfunction or urinary incontinence |
| MX2009009183A (es) * | 2007-02-28 | 2009-09-07 | Inotek Pharmaceuticals Corp | Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos. |
| WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
| JP2009196973A (ja) * | 2007-09-26 | 2009-09-03 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 |
| JP2009096804A (ja) * | 2007-09-26 | 2009-05-07 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤 |
| US20100137976A1 (en) * | 2008-12-02 | 2010-06-03 | Medtronic Vascular, Inc. | Systems and Methods for Treating Heart Tissue Via Localized Delivery of Parp Inhibitors |
| WO2010077663A2 (en) * | 2008-12-08 | 2010-07-08 | Inotek Pharmaceuticals Corporation | Substituted tetracyclic 1h-indeno (1,2-b) pyridine-2 (5h)-one analogs thereof and uses thereof |
| ITFI20090005A1 (it) * | 2009-01-19 | 2010-07-20 | Alberto Chiarugi | Formulazioni farmaceutiche per indurre immunosoppressione attraverso l'inibizione del fenomeno dell'epitope spreading e loro uso. |
| EP3613729A1 (en) * | 2009-06-10 | 2020-02-26 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compounds |
| KR101034051B1 (ko) * | 2009-07-13 | 2011-05-11 | (재)광주테크노파크 | 신규한 이소인돌로[2,1-ｂ]이소퀴놀린온 유도체 및 이를 함유하는 항암제 조성물 |
| EP2280011A1 (en) * | 2009-07-28 | 2011-02-02 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Condensed pyridine derivatives useful as potent inhibitors of the protein kinase CK2 |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| WO2011094416A1 (en) | 2010-01-27 | 2011-08-04 | Purdue Research Foundation | Substituted norindenoisoquinolines, syntheses thereof, and methods of use |
| HUP1000243A2 (en) | 2010-05-06 | 2012-01-30 | Avidin Kft | 8-hidroxy-quinoline derivatives |
| CN102250000A (zh) * | 2010-05-17 | 2011-11-23 | 中国人民解放军第二军医大学 | 茚并喹啉酮类化合物及其制备方法和用途 |
| EP2578587B1 (en) * | 2010-05-24 | 2016-09-07 | Hande Starlake Bioscience Co., Ltd. | Pyrazole derivatives |
| US9073920B2 (en) | 2010-08-17 | 2015-07-07 | Purdue Research Foundation | Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor |
| CA2808210C (en) | 2010-08-20 | 2019-10-01 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compounds having alk inhibitory activity and compositions thereof |
| TW201307347A (zh) | 2010-11-01 | 2013-02-16 | Arqule Inc | 經取代苯並－咪唑並－吡啶並－二氮呯化合物 |
| US9682990B2 (en) | 2011-05-25 | 2017-06-20 | Purdue Research Foundation | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors |
| US9328073B2 (en) | 2011-05-25 | 2016-05-03 | Purdue Research Foundation | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors |
| US8912213B2 (en) | 2012-04-13 | 2014-12-16 | Purdue Research Foundation | Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (TDP1)- topoisomerase I (TOP1) inhibitors |
| US8686146B2 (en) | 2012-07-13 | 2014-04-01 | Purdue Research Foundation | Azaindenoisoquinoline topoisomerase I inhibitors |
| US9034870B2 (en) | 2012-07-13 | 2015-05-19 | Purdue Research Foundation | Azaindenoisoquinoline topoisomerase I inhibitors |
| SI2902029T1 (sl) | 2012-09-25 | 2018-11-30 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor ret |
| WO2014063189A1 (en) * | 2012-10-23 | 2014-05-01 | Adelaide Research & Innovation Pty Ltd | Methods and products for preventing and/or treating a stress induced cardiomyopathy |
| EP3010055B1 (en) * | 2013-06-11 | 2021-10-20 | Idemitsu Kosan Co., Ltd | Material for organic electroluminescent elements, organic electroluminescent element using same, and electronic device |
| WO2015163448A1 (ja) | 2014-04-25 | 2015-10-29 | 中外製薬株式会社 | ４環性化合物を高用量含有する製剤 |
| WO2015163447A1 (ja) | 2014-04-25 | 2015-10-29 | 中外製薬株式会社 | ４環性化合物の新規結晶 |
| TWI831347B (zh) | 2014-08-08 | 2024-02-01 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
| CA2973857C (en) | 2015-01-16 | 2023-11-07 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
| DE102016214092A1 (de) | 2016-07-29 | 2018-02-01 | Alligator Ventilfabrik Gmbh | Befestigungsvorrichtung zum Befestigen eines Messsensors, insbesondere Reifendrucksensors, und Verfahren zum Montieren eines Messsensors |
| WO2018197461A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| EP4316598B1 (en) | 2018-06-29 | 2025-06-18 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising a poorly soluble basic agent |
| BR112021001145A2 (pt) | 2018-09-04 | 2021-04-20 | Chugai Seiyaku Kabushiki Kaisha | método para a produção de composto tetracíclico |
| EP3870572A1 (en) * | 2018-10-23 | 2021-09-01 | Myelopro Diagnostics and Research GmbH | Compounds targeting mutant calreticulin |
| CN118146221B (zh) * | 2024-05-13 | 2024-10-25 | 南京市鸿舜医药科技有限公司 | 一种吡咯并[3,2-b]吡啶类拓扑异构酶抑制剂、制法及其药物组合物和应用 |
| CN118221674B (zh) * | 2024-05-27 | 2025-01-28 | 南京市鸿舜医药科技有限公司 | 一种吡咯并[3,2-b]吡啶类Top/HDAC双靶点抑制剂、制法及其药物组合物和应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) * | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| IT1054655B (it) * | 1975-08-27 | 1981-11-30 | Lepetit Spa | Derivati condensati del l isochinolina |
| US4263304A (en) * | 1978-06-05 | 1981-04-21 | Sumitomo Chemical Company, Limited | 7 H-indolo[2,3-c]isoquinolines |
| GB2025932B (en) * | 1978-06-13 | 1982-10-27 | Sumitomo Chemical Co | Indoloisoquinolines and processes for producing them |
| US4623304A (en) * | 1981-12-08 | 1986-11-18 | Sanyo Electric Co., Ltd. | Hermetically sealed rotary compressor |
| US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| GB8828806D0 (en) * | 1988-12-09 | 1989-01-18 | Beecham Group Plc | Novel compounds |
| US5260316A (en) * | 1991-07-30 | 1993-11-09 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
| US5597831A (en) * | 1991-08-29 | 1997-01-28 | Vufb A.S | 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents |
| SK278794B6 (sk) * | 1991-08-29 | 1998-03-04 | V�Fb | 2-hydroxyetylaminosubstituované deriváty 5,11-diox |
| US5262564A (en) * | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| TW440562B (en) * | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| JP3643916B2 (ja) * | 1995-11-17 | 2005-04-27 | 大鵬薬品工業株式会社 | 新規な縮合インデン誘導体又はその塩 |
| AU8784698A (en) | 1997-08-15 | 1999-03-08 | Johns Hopkins University, The | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
| US6250301B1 (en) | 1997-08-28 | 2001-06-26 | Hortal Harm B.V. | Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6346536B1 (en) * | 1997-09-03 | 2002-02-12 | Guilford Pharmaceuticals Inc. | Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| JP2002515488A (ja) | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法 |
| WO2000010600A2 (en) * | 1998-08-24 | 2000-03-02 | Maxim Pharmaceuticals, Inc. | Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents |
| CA2347100C (en) | 1998-10-14 | 2010-12-14 | Purdue Research Foundation | Novel indenoisoquinolines as antineoplastic agents |
| DE59911249D1 (de) | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| US6387902B1 (en) | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
| US6201020B1 (en) | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| OA11749A (en) | 1999-01-11 | 2005-07-19 | Agouron Pharma | Tricyclic inhibitors of poly(adp-ribose)polymerases. |
| US6346535B1 (en) * | 1999-01-29 | 2002-02-12 | American Cyanamid Company | Fungicidal mixtures |
| AU779215B2 (en) * | 1999-07-16 | 2005-01-13 | Maxim Pharmaceuticals, Inc. | Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor |
| US6465448B1 (en) | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
| US6277990B1 (en) * | 1999-12-07 | 2001-08-21 | Inotek Corporation | Substituted phenanthridinones and methods of use thereof |
| US6723733B2 (en) * | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
| GB0017508D0 (en) | 2000-07-17 | 2000-08-30 | Novartis Ag | Antimicrobials |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| US20030096833A1 (en) * | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
| US6956035B2 (en) * | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
| JP2003267888A (ja) | 2002-03-15 | 2003-09-25 | Seishi Yoneda | 心停止液 |
| US6992088B2 (en) | 2002-08-09 | 2006-01-31 | Rutgers, The State University Of New Jersey | Nitro and amino substituted heterocycles as topoisomerase I targeting agents |
| JPWO2004043959A1 (ja) | 2002-11-12 | 2006-03-09 | 持田製薬株式会社 | 新規ｐａｒｐ阻害剤 |
| JP2007501857A (ja) * | 2003-02-28 | 2007-02-01 | イノテック ファーマシューティカルズ コーポレーション | 四環系ベンズアミド誘導体およびその使用方法 |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| KR20060123403A (ko) | 2003-12-01 | 2006-12-01 | 쿠도스 파마슈티칼스 리미티드 | 암 치료를 위한 ｄｎａ 손상 수복 억제제 |
| EA200601558A1 (ru) * | 2004-02-26 | 2007-08-31 | Инотек Фармасьютикалз Корпорейшн | Производные изохинолинов и способы их использования |
| US20050261288A1 (en) * | 2004-02-26 | 2005-11-24 | Prakash Jagtap | Tetracyclic lactam derivatives and uses thereof |
| CA2571001A1 (en) * | 2004-06-16 | 2006-01-26 | Inotek Pharmaceuticals Corporation | Methods for treating or preventing erectile dysfunction or urinary incontinence |
| US20060079510A1 (en) * | 2004-09-30 | 2006-04-13 | Kristoffer Hellstrand | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
| WO2006093677A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Tetracyclic sulfonamide compounds and methods of use thereof |
| JP2008531561A (ja) * | 2005-02-25 | 2008-08-14 | イノテック ファーマシューティカルズ コーポレイション | イソキノリン化合物およびその使用方法 |
| RU2007135362A (ru) * | 2005-02-25 | 2009-03-27 | Инотек Фармасьютикалз Корпорейшн (Us) | Тетрациклические амино- и карбоксамидосоединения и способ их применения |
| CN101316592A (zh) * | 2005-08-24 | 2008-12-03 | 伊诺泰克制药公司 | 茚并异喹啉酮类似物及其用法 |
-
2004
- 2004-02-26 JP JP2006532301A patent/JP2007501857A/ja active Pending
- 2004-02-26 US US10/788,228 patent/US7217709B2/en not_active Expired - Fee Related
- 2004-02-26 CN CNB2004800114280A patent/CN100398519C/zh not_active Expired - Fee Related
- 2004-02-26 PL PL378331A patent/PL378331A1/pl unknown
- 2004-02-26 CA CA002517260A patent/CA2517260A1/en not_active Abandoned
- 2004-02-26 AU AU2004258801A patent/AU2004258801A1/en not_active Abandoned
- 2004-02-26 RU RU2005130169/04A patent/RU2005130169A/ru not_active Application Discontinuation
- 2004-02-26 WO PCT/US2004/005737 patent/WO2005009398A2/en not_active Ceased
- 2004-02-26 KR KR1020057016126A patent/KR20050118169A/ko not_active Withdrawn
- 2004-02-26 EP EP04775806A patent/EP1603567A4/en not_active Withdrawn
- 2004-02-26 BR BRPI0407757-1A patent/BRPI0407757A/pt not_active IP Right Cessation
-
2007
- 2007-04-12 US US11/786,627 patent/US20070249653A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN100398519C (zh) | 2008-07-02 |
| CA2517260A1 (en) | 2005-02-03 |
| WO2005009398A3 (en) | 2005-09-29 |
| PL378331A1 (pl) | 2006-03-20 |
| KR20050118169A (ko) | 2005-12-15 |
| US20040229895A1 (en) | 2004-11-18 |
| BRPI0407757A (pt) | 2006-02-14 |
| AU2004258801A1 (en) | 2005-02-03 |
| EP1603567A2 (en) | 2005-12-14 |
| US7217709B2 (en) | 2007-05-15 |
| US20070249653A1 (en) | 2007-10-25 |
| JP2007501857A (ja) | 2007-02-01 |
| CN1780624A (zh) | 2006-05-31 |
| WO2005009398A2 (en) | 2005-02-03 |
| EP1603567A4 (en) | 2006-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005130169A (ru) | Тетрациклические производные бензамида и способы их применения | |
| JP2007501857A5 (https=) | ||
| KR920009796A (ko) | 3-아미도인돌릴 유도체 | |
| RU2005130159A (ru) | Изохинолиновые производные и способы их применения | |
| KR930000512A (ko) | 헤테로사이클 화합물, 이의 제조방법 및 용도 | |
| JP2010536887A5 (https=) | ||
| RU2004137480A (ru) | Ингибиторы вируса гепатита с | |
| RU2005119633A (ru) | Антивирусные нуклеозидные производные | |
| JP2001525359A5 (https=) | ||
| WO2002057252A3 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| RU2010111551A (ru) | Замещенные индольные производные и способы их применения | |
| CA2672652A1 (en) | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | |
| JP2005508933A5 (https=) | ||
| JP2005502681A5 (https=) | ||
| RU96120173A (ru) | Бензотиофен, бензофуран и индолтиазепиноны, оксазепиноны и диазепиноны в качестве ингибиторов клеточной адгезии и в качестве ингибиторов вича | |
| RU97109847A (ru) | Производные аминотетразола, полезные как ингибиторы синтазы оксида азота | |
| RU2003120069A (ru) | Замещенные 2-анилино-бензимидазолы, их применение в качестве ингибиторов na+/h+-обмена, а также содержащее их лекарственное средство | |
| ATE346850T1 (de) | 5-ht4-rezeptor-antagonisten | |
| JP2008500366A5 (https=) | ||
| CA2626032A1 (en) | Camptothecin derivatives as chemoradiosensitizing agents | |
| RU2006103858A (ru) | Способ лечения пролиферативных заболеваний | |
| RU2007135355A (ru) | Производные изохинолина и способы их применения | |
| CA2708113C (en) | Compounds for use in the treatment of cancer | |
| RU2001126063A (ru) | Производные пиридазин-3-она и содержащие их лекарственные средства | |
| WO2004075858A3 (en) | Flavone acetic acid analogs and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080724 |